Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
Revenue (TTM)
$9 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
24.51
EV/EBITDA
-1.6
Div. Yield
174.7 %
Debt to Equity
0
Book Value
$--
EPS
$5
Face value
--
Shares outstanding
1,349,960
CFO
$-47.42 Mln
EBITDA
$-51.24 Mln
Net Profit
$-102.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Guardion Health Sciences (GHSI)
| -- | -- | -1.5 | -38.3 | -50.2 | -49.3 | -- |
|
BSE Sensex*
| -14.8 | -11.3 | -15.4 | -5.2 | 6.9 | 7.6 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Guardion Health Sciences (GHSI)
| -26.4 | -77.6 | -74.0 | 88.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to... support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California. Read more
Independent Chairman & Secretary
Mr. Robert Neal Weingarten
Independent Chairman & Secretary
Mr. Robert Neal Weingarten
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Guardion Health Sciences Inc (GHSI) is $3.22 (NASDAQ) as of 23-Jan-2025 09:30 EDT. Guardion Health Sciences Inc (GHSI) has given a return of -50.15% in the last 3 years.
Since, TTM earnings of Guardion Health Sciences Inc (GHSI) is negative, P/E ratio is not available.
The P/B ratio of Guardion Health Sciences Inc (GHSI) is 0.32 times as on 23-Jan-2025, a 94 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
43.09
|
0.84
|
|
2022
|
-0.01
|
0.01
|
|
2021
|
-31.94
|
35.44
|
|
2020
|
-0.04
|
0.04
|
|
2019
|
-0.01
|
0.01
|
The 52-week high and low of Guardion Health Sciences Inc (GHSI) are Rs -- and Rs -- as of 02-Apr-2026.
Guardion Health Sciences Inc (GHSI) has a market capitalisation of $ 4 Mln as on 23-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Guardion Health Sciences Inc (GHSI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.